Pictet Asset Management Holding SA Decreases Stake in Pfizer Inc. $PFE

Pictet Asset Management Holding SA decreased its holdings in Pfizer Inc. (NYSE:PFE) by 6.1% during the 4th quarter, HoldingsChannel reports. The fund owned 2,751,519 shares of the biopharmaceutical company’s stock after selling 178,941 shares during the quarter. Pictet Asset Management Holding SA’s holdings in Pfizer were worth $68,515,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Physician Wealth Advisors Inc. boosted its stake in Pfizer by 4.6% in the fourth quarter. Physician Wealth Advisors Inc. now owns 9,525 shares of the biopharmaceutical company’s stock valued at $237,000 after acquiring an additional 418 shares during the period. Inscription Capital LLC grew its holdings in Pfizer by 2.4% during the fourth quarter. Inscription Capital LLC now owns 51,462 shares of the biopharmaceutical company’s stock worth $1,281,000 after acquiring an additional 1,216 shares during the period. Quest 10 Wealth Builders Inc. boosted its holdings in Pfizer by 584.9% during the fourth quarter. Quest 10 Wealth Builders Inc. now owns 1,993 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 1,702 shares in the last quarter. St. Johns Investment Management Company LLC boosted its holdings in Pfizer by 2.2% during the fourth quarter. St. Johns Investment Management Company LLC now owns 26,573 shares of the biopharmaceutical company’s stock worth $662,000 after buying an additional 580 shares in the last quarter. Finally, Facet Wealth Inc. bought a new stake in Pfizer during the fourth quarter worth approximately $322,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Trading Down 1.3%

PFE opened at $26.45 on Wednesday. The company has a quick ratio of 0.87, a current ratio of 1.16 and a debt-to-equity ratio of 0.71. The company has a fifty day moving average of $27.20 and a 200-day moving average of $26.09. Pfizer Inc. has a twelve month low of $21.97 and a twelve month high of $28.75. The stock has a market cap of $150.37 billion, a PE ratio of 19.44 and a beta of 0.43.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The firm had revenue of $17.56 billion for the quarter, compared to the consensus estimate of $16.93 billion. During the same quarter in the prior year, the company posted $0.63 earnings per share. The business’s revenue was down 1.2% on a year-over-year basis. On average, sell-side analysts predict that Pfizer Inc. will post 2.98 EPS for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 12th. Stockholders of record on Friday, May 8th will be paid a $0.43 dividend. The ex-dividend date is Friday, May 8th. This represents a $1.72 annualized dividend and a dividend yield of 6.5%. Pfizer’s dividend payout ratio is presently 126.47%.

Analyst Ratings Changes

PFE has been the topic of several recent analyst reports. Bank of America dropped their price target on Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Thursday, April 9th. Argus raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $35.00 target price for the company in a research report on Monday, March 2nd. Daiwa Securities Group downgraded shares of Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 target price for the company. in a research report on Thursday, February 12th. BMO Capital Markets restated an “outperform” rating and issued a $30.00 price objective on shares of Pfizer in a research note on Monday, March 9th. Finally, Barclays assumed coverage on shares of Pfizer in a research note on Thursday, February 19th. They issued an “underweight” rating and a $25.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, fourteen have given a Hold rating and three have issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $28.48.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer reached settlement agreements with three generic makers that effectively extend exclusivity on its heart drug, keeping generic rivals out of the U.S. market until about 2031 — a meaningful revenue-protection outcome for the product. Pfizer secures deals to keep heart drug free of generic rivals until 2031
• Positive Sentiment: Multiple outlets report the settlements specifically extend the effective U.S. patent life for Vyndamax (the branded heart drug), which should delay revenue erosion from generics and supports medium-term cash flow. Pfizer Stock Is Declining Today: What’s Happening?
• Neutral Sentiment: Analyst and media pieces revisit Pfizer’s dividend and income appeal (high yield), which supports longer?term buy-and-hold interest even amid short-term volatility. Is Pfizer (PFE) One of the Best Fortune 500 Dividend Stocks to Invest in Right Now?
• Neutral Sentiment: Broader comparisons and strategy pieces (Novo Nordisk vs. Pfizer; buy/sell/hold guidance) highlight pipeline choices and longer-term growth questions — useful context but not immediate price drivers. Should You Buy, Sell, or Hold Pfizer at $27?
• Negative Sentiment: Zacks warns Q1 earnings are expected to decline and that Pfizer may lack the setup for an earnings beat this quarter — a near-term catalyst likely contributing to selling pressure. Earnings Preview: Pfizer (PFE) Q1 Earnings Expected to Decline
• Negative Sentiment: Market wrap and news roundups note Pfizer underperformed the broader market today — analysts attribute that to profit-taking, elevated volume of selling, and investor concern about near-term sales/earnings momentum despite the patent settlements. Why Pfizer (PFE) Dipped More Than Broader Market Today
• Negative Sentiment: Consumer-facing coverage flags the stock decline and summarizes investor uncertainty, reinforcing short-term negative sentiment and contributing to momentum-based selling. Pfizer stock is declining today: What’s happening?

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.